Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent

Cancer Research

Volumn 60, Issue 1, 2000, Pages 86-91

  Bernhard, Eric J ^a   Mitchell, James B ^a   Deen, Dennis ^c   Cardell, Monika ^c   Rosenthal, David I ^a   Brown, J Martin ^b,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANIDAZOLE; GADOLINIUM; GADOLINIUM TEXAPHYRIN; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CELL HYPOXIA; CELL SURVIVAL; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIZATION;

ANIMALS; CELL DIVISION; CELL HYPOXIA; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; HT29 CELLS; HUMANS; METALLOPORPHYRINS; MICE; MICE, SCID; RADIATION-SENSITIZING AGENTS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0033958684     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Young, S. W., Qing, F., Harriman, A., Sessler, J. L., Dow, W. C., Mody, T. D., Hemmi, G. W., Hao, Y., and Miller, R. A. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc. Natl. Acad. Sci. USA, 93: 6610-6615, 1996.
2. Rosenthal, D. I., Nurenberg, P., Becerra, C. R., Frenkel, E. P., Carbone, D. P., Lum, B. L., Miller, R., Engel, J., Young, S., Miles, D., and Renschler, M. F. A Phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clinical Cancer Res., 5: 739-745, 1999.
3. Brown, J. M., Yu, N. Y., Brown, D. M., and Lee, W. W. SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int. J. Radiat. Oncol. Biol. Phys., 7: 695-703, 1981.
4. Dabrow, M. B., Katz, H., O'Dwyer, P. J., Afshar, C., and Glusker, J. P. Molecular dimensions and properties of N-[1-(2-hydroxyethyl)-2-nitro-1H-imidazol-1-y1]acetamide (SR2508). Arch. Biochem. Biophys., 302: 259-264, 1993.
5. Young, S W., Qing, F., Harriman, A., Sessler, J. L., Dow, W. C., Mody, T. D., Hemmi, G. W., Hao, Y., and Miller, R. A. Proc. Natl. Acad. Sci. USA, 96: 2569, 1999.
6. Miller, R. A., Woodburn, K., Fan, Q., Renschler, M., Sessler, J. L., and Koutcher, J. A. In vivo animal studies with Gd-tex as a radiation enhancer. Int. J. Radiat. Oncol. Biol. Phys., 45: 981-999, 1999.
7. Rosenthal, D. I, Becerra, C., Frenkel, E., Nurenberg, P., Carbone, D., Young, S., Miller, R., Engel, J., Holm, F., and Renschler, M. F. Phase I single dose trial of the radiation sensitizer gadolinium-texaphrin (Gd-Tex) confirms tumor selectivity. Annu. Meeting Am. Soc. Clin. Oncol., 16: 480a, 1997.
8. Klausner, R. D. The nation's investment in cancer research. A budget proposal for fiscal year 1999, p. 37, 1998.
9. Industry sponsored clinical trials. Cancer Econ., pp. 4-5, 1998.
10. Ramsay, J., Birrell, G., Baumann, K., Bodero, A., Parsons, P., and Lavin, M. Radiosensitive melanoma cell line with mutation of the gene for ataxia-telangectasia. Br. J. Cancer, 77: 1-4, 1998.
11. Kirchgessner, C. U., Patil, C. K., Evans, J. W., Cuomo, C. A., Fried, L. M., Carter, T., Oettinger, M. A., and Brown, J. M. DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect. Science (Washington DC), 267: 1178-1183, 1995.
12. Adams, G. E., Flockhart, I. R., Smithen, C. E., Stratford, I. J., Wardman, P. and Watts, M. E. Electron-affinic sensitization. VII. A correlation between structures, one electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat. Res., 67: 9-20, 1976.
13. Horsman, M. R., Chaplin, D. J., and Brown, J. M. Tumor radiosensitization by nicotinamide: a result of improved blood perfusion and oxygenation. Radiat. Res., 118: 139-150, 1989.
14. Brown, J. M., Twentyman, P.R., and Zamvil, S. S. Response to the RIF-1 tumor in vitro and in C3H/Km mice to X-radiation (cell survival, regrowth delay, and tumor control), chemotherapeutic agents, and activated macrophages. J. Natl. Cancer Inst., 64: 605-611, 1980.
15. Rockwell, S. C., Kallman, R. F., and Fajardo, L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J. Natl. Cancer Inst., 49: 735-749, 1972.